Daix (France), Long Island City (New York, United States), on June 21, 2024 -
Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage
biopharmaceutical company focused on the development of oral small molecule
therapies for the treatment of metabolic dysfunction-associated steatohepatitis
("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other
diseases with significant unmet medical needs, today announced the results of
the votes of its Combined Shareholders' Meeting.
The Combined Shareholders' Meeting was held on Thursday June 20, 2024 at 9 a.m.
at Hôtel Castel Burgond, 3 route de Troyes, 21121 Daix (France), under the
chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and
cofounder of Inventiva.
Mr. Frederic Cren proceeded to the usual formalities of the opening of the
meeting, in particular to the constitution of the Bureau by appointing Mr.
Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Dorian Raynaldy,
as secretary of the general meeting.
All the resolutions submitted to vote have been adopted by the shareholders,
with the exception of the 30(th) resolution, which had been the subject of a
negative recommendation by the Board of Directors. The 30(th) resolution would
have empowered the Board of Directors to decide on share capital increases
reserved for members of a company savings plan to be set up by the Company.
Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined
Shareholders' Meeting approved, without modification, the compensation policy
for corporate officers as presented in the 2023 Universal Registration Document
(Part 3.5.1, pages 147 and seq.).
Information on the results of the votes is detailed below:
* Total number of shares composing the share capital: 52 477 188
* Total number of shares with voting rights: 52 346 516
+----------------------------------+----------------------------------+
| Ordinary part | Extraordinary part |
+------------+----------+----------+------------+----------+----------+
|Shareholders| Shares | Votes |Shareholders| Shares | Votes |
+------------+------------+----------+----------+------------+----------+----------+
|Shareholders| | | | | | |
| present | 3 | 14 120 | 14 120 | 3 | 14 120 | 14 120 |
+------------+------------+----------+----------+------------+----------+----------+
| Proxy to | | | | | | |
| third | | | | | | |
| parties | 0 | 0 | 0 | 0 | 0 | 0 |
+------------+------------+----------+----------+------------+----------+----------+
|Proxy to the| | | | | | |
| Chairman | 146 |4 203 203 |4 285 983 | 146 |4 203 203 |4 285 983 |
+------------+------------+----------+----------+------------+----------+----------+
| Mail votes | 67 |28 881 338|41 012 196| 67 |28 881 338|41 012 196|
+------------+------------+----------+----------+------------+----------+----------+
| TOTAL | 216 |33 098 661|45 312 299| 216 |33 098 661|45 312 299|
+------------+------------+----------+----------+------------+----------+----------+
| Quorum | 63,229 % | 63,229 % |
+------------+----------------------------------+----------------------------------+
VOTE RESULTS
Ordinary Resolutions
+----------+-------+-----------------+-------------+----------+----------+-----------+-----------+---------+-------+-------+
| | | For | Against |Abstention| | |Proportion | | | |
| | +----------+------+-------+-----+-------+--+ | | of | | | |
| | | | | | | | | Total | Number of |represented| Non- | | |
| | | | | | | | |number of |represented| share | voting |Invalid| |
|Resolution|Result | Votes | % | Votes | % | Votes |% |votes cast| shares | capital | votes | votes |Quorum |
+----------+-------+----------+------+-------+-----+-------+--+----------+-----------+-----------+---------+-------+-------+
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | |44 619 134|> |3 250 |Â